Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Voyager Therapeutics excels in 2022, poised for CNS therapeutic breakthroughs

Voyager Therapeutics demonstrated strong performance in 2022, leveraging key partnerships and advancements in their pipeline programs to drive innovation and growth in the CNS therapeutics space.
While facing challenges in operational clarity and regulatory hurdles, the company's scientific strengths and financial stability position it well to capitalize on opportunities for expanding collaborations and advancing novel therapeutic approaches.
With a focus on CNS delivery, tissue targeting, and surrogate markers, Voyager is poised to make significant strides in addressing neurological disorders and enhancing treatment efficacy, offering potential value for investors and patients alike.

Voyager Therapeutics reports strong Q1 earnings and strategic advancements

Voyager Therapeutics showcased robust financial performance and strategic advancements in neurotherapeutics and gene therapy, positioning the company for future growth.
While facing challenges related to animal model predictability and reimbursement considerations, Voyager is actively leveraging strengths in diversified therapeutic approaches and strategic partnerships.
Opportunities lie in exploring synergistic treatments, proactive risk mitigation, and innovative therapeutic strategies to address complex neurological disorders effectively.
Overall, Voyager's focus on innovation, strategic partnerships, and comprehensive drug development approaches underscores its commitment to advancing treatments for neurological diseases.

Voyager Therapeutics excels in Q2, poised for neurogenetic medicine expansion

Voyager Therapeutics demonstrated strong financial health, innovative advancements in CNS programs, and strategic partnerships driving revenue growth. While facing challenges in R&D management and program milestones, the company's opportunities lie in upcoming milestones and expansion in neurogenetic medicine.

Voyager Therapeutics advances CNS gene therapy with strong partnerships and cash balance

Voyager Therapeutics is making strides in CNS gene therapy delivery with strong financial backing
Facing challenges in toxicology studies and patient recruitment while eyeing collaboration opportunities
Opportunities lie in biomarker utilization, partnership models, and advancing key programs towards clinical milestones

Voyager Therapeutics reports robust earnings and advances in neurogenetic therapies

Voyager Therapeutics showcased a strong financial performance, progress in their pipeline programs, and a focus on innovation and differentiation in the gene therapy space.
While facing competition and regulatory challenges, the company's strategic strengths, collaborations, and positive data present opportunities for future growth and impact.
Analysts' inquiries into program progress and regulatory timelines underscore investor interest in Voyager's development trajectory and the potential of their neurogenetic therapies.
With a robust financial position, promising pipeline advancements, and a commitment to unique approaches, Voyager is poised to make significant strides in the treatment of neurological disorders.

Voyager Therapeutics excels in Q1, eyes Alzheimer's breakthroughs

Voyager Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2024.
The company's focus on neurogenetic medicine and innovative gene therapy programs is a key strength.
Challenges include demonstrating efficacy in ALS therapy and optimizing brain delivery methods.
Opportunities lie in exploring novel treatment approaches and anticipating key data releases.

Voyager Therapeutics excels in Q2 with innovative pipeline advancements

Voyager Therapeutics demonstrated strong performance in Q2 2024, focusing on key milestones, tau-directed programs, and derisking strategies.
While facing challenges in program optimization and competitive positioning, the company's strengths lie in innovative pipeline advancements and financial stability.
Opportunities for multi-organ specificity, disease-specific programs, and treatment refinement position Voyager for continued growth and therapeutic innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Boeing

Caterpillar

Celsius Holdings

Chevron

Enphase Energy

JPMorgan Chase & Co

McDonald's

Merck

Northern Oil and Gas

Sensus Healthcare

Visa

Two new Breakout Stocks for Week 2 with better than 10% short-term upside potential and one Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. Momentum Gauge trading signal turned positive this week and new portfolios are all positive with strong gains to start the new year.

MDA Breakout Stocks Week 2 - January 2023: High-Frequency Gainers To Give You An Edge

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 10:30 a.m. PT / 1:30 p.m. ET.

Voyager Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25 years of experience as a healthcare leader, investor and entrepreneur; she most recently served as President, CEO and Director of clinical-stage biotechnology company InCarda Therapeutics, Inc.

Voyager Therapeutics Appoints Grace E. Colón, Ph.D.

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Alfred Sandrock - Chief Executive Officer Peter Pfreundschuh - Chief Financial Officer Todd Carter - Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird Philip Nadeau - Cowen and Company Laura Chico - Wedbush Yung Zhong - BTIG Dane Leone - Raymond James Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to Voyager Therapeutics Third Quarter 2022 Conference Call.

Voyager Therapeutics, Inc. (VYGR) Q3 2022 Earnings Call Transcript

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates

- Voyager's TRACER TM capsid platform validated by Pfizer option exercise -

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to review its financial and operating results.

Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy?

- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 -

Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Option exercise triggers $10 million payment to Voyager, further validating the potential of the TRACER capsid platform

Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland.

Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy

AbbVie

ADMA Biologics

Geron

Prometheus Biosciences

SIGA Technologies

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

7 Top-Rated Biotech Stocks to Buy for Q4

Expansion of Senior Leadership Team enhances Voyager's ability to articulate and execute on its vision to enable and advance transformational treatments for CNS diseases Expansion of Senior Leadership Team enhances Voyager's ability to articulate and execute on its vision to enable and advance transformational treatments for CNS diseases

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

Voyager Digital had 3.5 million customers, and many are now doing everything they can to try and get some of their money back.

Voyager customer lost $1 million saved over 24 years and is one of many now desperate to recoup funds

Court proceedings and financial documents detail how complicated relationships were between the two Bankman-Fried firms — Alameda and FTX — and Voyager Digital.

Sam Bankman-Fried's crypto firms had deep ties to Voyager Digital and its bankruptcy wipeout

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Julie Burek - Vice President of Finance Dr. Al Sandrock - Chief Financial Officer Dr. Todd Carter - Senior Vice President of Research Conference Call Participants Jack Allen - Baird Divya Rao - Cowen & Company Yung Zhong - BTIG Operator Good day, and welcome to Voyager Therapeutics Second Quarter 2022 Conference Call. All participants are now in a listen-only mode.

Voyager Therapeutics, Inc. (VYGR) CEO Dr. Al Sandrock on Q2 2022 Results - Earnings Call Transcript

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022. Subsequently, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss its financial and operating results and provide a corporate update.

Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Catherine J. Mackey, Ph.D. to its Board of Directors. Dr. Mackey is a seasoned life science executive with more than thirty years of operational experience highlighted by her tenure as Senior Vice President, Global Research & Development, for Pfizer, Inc.

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D.

VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing

Voyager Therapeutics' TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis

Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™  AAV9- and AAV5-derived capsids

News for Voyager Therapeutics Stock (VYGR)